Oramed Pharmaceuticals (NASDAQ:ORMP) Issues Quarterly Earnings Results, Misses Estimates By $0.16 EPS

Oramed Pharmaceuticals (NASDAQ:ORMP) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.16), Zacks reports. The company had revenue of $2.00 million during the quarter.

Oramed Pharmaceuticals Stock Down 2.3%

Shares of ORMP opened at $2.15 on Friday. Oramed Pharmaceuticals has a 52-week low of $1.82 and a 52-week high of $3.09. The company has a market capitalization of $87.83 million, a PE ratio of 19.55 and a beta of 1.65. The stock has a fifty day simple moving average of $2.25 and a two-hundred day simple moving average of $2.31.

Analysts Set New Price Targets

Separately, StockNews.com downgraded Oramed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.